Evidence map›Paper›PMID 42207410›Full record

ArticleDigestive diseases and sciences2026

Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.

Alvina, Huda Jaffar, Chidera N Onwuzo, Abdelkader Chaar, Mohamed Eisa

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

AlvinaDepartment of Internal Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA. alvina.1898@gmail.com.ORCID http://orcid.org/0009-0007-8273-5252
Huda JaffarDepartment of Internal Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA.ORCID http://orcid.org/0000-0003-4805-0691
Chidera N OnwuzoDepartment of Internal Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA.ORCID http://orcid.org/0009-0008-5674-3424
Abdelkader ChaarDivision of Gastroenterology and Hepatology, SUNY Upstate Medical University, Syracuse, NY, USA.ORCID http://orcid.org/0000-0002-4259-0606
Mohamed EisaDivision of Gastroenterology and Hepatology, SUNY Upstate Medical University, Syracuse, NY, USA.ORCID http://orcid.org/0000-0001-5120-4060

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiliary adverse events (AEs) have been reported with glucagon-like peptide-1 receptor agonists (GLP-1RAs), but within-class differences remain unclear.

methodsWe conducted a disproportionality analysis of FAERS comparing biliary outcomes (cholelithiasis, cholecystitis, biliary colic, bile duct stone, and cholangitis) across semaglutide, tirzepatide, liraglutide, exenatide, and dulaglutide; semaglutide was used as the reference agent. Proportional reporting ratios (PRR), reporting odds ratios (ROR), 95% confidence intervals, and Fisher exact tests were calculated. Subgroup analyses and sensitivity analyses were performed.

resultsAfter deduplication, 3460 reports were analyzed: semaglutide 1797, tirzepatide 1363, liraglutide 1033, exenatide 999, and dulaglutide 574. Compared with semaglutide, exenatide and tirzepatide showed lower reporting for bile duct stone (PRR 0.39 and 0.58), while exenatide and dulaglutide showed lower reporting for biliary colic (PRR 0.30 and 0.50). Dulaglutide showed higher reporting for cholangitis (PRR 1.65). Exenatide, liraglutide, and tirzepatide showed higher reporting for cholecystitis (PRR 1.12, 1.07, and 1.05) and cholelithiasis (PRR 1.33, 1.21, and 1.15). Subgroup findings were consistent with heterogeneity mainly observed for bile duct stone and biliary colic. Sensitivity analyses was largely concordant, although rarer outcomes lost significance.

conclusionsBiliary AE reporting varies across GLP-1RAs, highlighting agent-specific differences within class and the need for individualized prescribing and counseling.

Indexed as

Adverse Drug Reaction Reporting SystemsBiliary Tract DiseasesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsExenatideGlucagon-Like PeptidesHumansImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsSemaglutideTirzepatidedulaglutideExenatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsSemaglutideTirzepatideBiliary adverse eventsDisproportionality analysisFDA adverse event reporting systemGlucagon-like peptide-1 receptor agonists

Identifiers

PMID42207410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.